Proteomic meta-study harmonization, mechanotyping and drug repurposing candidate prediction with ProHarMeD.

ABSTRACT: Proteomics technologies, which include a diverse range of approaches such as mass spectrometry-based, array-based, and others, are key technologies for the identification of biomarkers and disease mechanisms, referred to as mechanotyping. Despite over 15,000 published studies in 2022 alone, leveraging publicly available proteomics data for biomarker identification, mechanotyping and drug target identification is not readily possible. Proteomic data addressing similar biological/biomedical questions are made available by multiple research groups in different locations using different model organisms. Furthermore, not only various organisms are employed but different assay systems, such as in vitro and in vivo systems, are used. Finally, even though proteomics data are deposited in public da

SUBMITTER: Adamowicz K 

PROVIDER: S-EPMC10564802 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature